Understanding Trodelvy Prescribing Information: Dosage, Administration, and Adverse Reactions
When it comes to cancer treatment, precision is the key. In recent years, there has been a surge in drugs designed to treat specific forms of cancer. Trodelvy is one such example. It’s a medication used in the treatment of metastatic triple-negative breast cancer (mTNBC), a challenging-to-treat condition. In this article, we’ll discuss Trodelvy prescribing information, including dosage, administration, and adverse reactions.
What is Trodelvy, and How Does it Work?
Trodelvy (sacituzumab govitecan) is an FDA-approved medication for the treatment of mTNBC in patients who have already received at least two prior treatments. Trodelvy is designed to target Trop-2, a cell surface protein present in several types of cancer, including mTNBC. The drug works by delivering a chemotherapy drug, irinotecan, to the cancer cells via a monoclonal antibody that specifically binds with Trop-2.
Dosage and Administration
The recommended dosage for Trodelvy is 10 mg/kg of body weight administered via intravenous infusion over one hour on days one and eight of a 21-day treatment cycle until disease progression or unacceptable toxicity occurs. Patients should be closely monitored during and after the infusion for any potential adverse reactions. The infusion should be stopped or slowed if an adverse reaction occurs.
Adverse Reactions
As with any medication, Trodelvy can cause adverse reactions that range from mild to severe. The most common adverse reactions (reported in at least 25% of patients) include nausea, fatigue, diarrhea, vomiting, constipation, decreased appetite, hair loss, rash, and abdominal pain. The most serious adverse reactions include neutropenia and diarrhea. Patients should inform their healthcare providers promptly if any adverse reactions occur.
Conclusion
In conclusion, Trodelvy is a promising medication for the treatment of mTNBC, with a specific mechanism of action that targets Trop-2. The drug is administered via intravenous infusion at a recommended dosage of 10 mg/kg on day one and eight of a 21-day treatment cycle until disease progression or unacceptable toxicity occurs. Patients should be monitored closely for any potential adverse reactions. As always, patients should consult with their healthcare providers to determine if Trodelvy is a suitable treatment option for them.
